The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
about
Acquired pure red cell aplasia: updated review of treatmentTreatment of autoimmune hemolytic anemiasFifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory itp in adults.Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy.Adult idiopathic thrombocytopenic purpura.Monoclonal antibodies in the treatment of autoimmune cytopenias.Immune thrombocytopenic purpura - current management practices.Autoimmune thrombocytopenia.Management of Evans syndrome.Alemtuzumab for B-cell chronic lymphocytic leukemia.A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia.Current treatment options for primary immune thrombocytopenia.ITP: a historical perspective.Immune thrombocytopenic purpura: historical perspective, current status, recent advances and future directions.Contemporary treatment of immune thrombocytopenia.Alemtuzumab plus cyclosporine treatment of the autoimmune hemolytic anemia in an adult bowel transplant.How I manage Evans Syndrome and AIHA cases in children.Mouse Models for Immune-Mediated Platelet Destruction or Immune Thrombocytopenia (ITP).Acquired pure red cell aplasia in a patient of rheumatoid arthritis.Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades.Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemiaA review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation.Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 studyAnemia of Central Origin.Chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.Emerging biologics in the treatment of uveitis.Autoimmune hemolytic anemia: classification and therapeutic approaches.Pathophysiologic mechanisms, clinical features and treatment of idiopathic neutropenia.Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders.Classification and therapeutic approaches in autoimmune hemolytic anemia: an update.Antibodies in the treatment of aplastic anemia.Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab).Current approaches for the treatment of autoimmune hemolytic anemia.Immunotherapy treatments of warm autoimmune hemolytic anemia.Current treatment strategies in autoimmune hemolytic disorders.Autoimmune haemolytic anaemia emerging during Campath treatment in a patient with CD5 negative chronic lymphocytic leukaemiaIncidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H.A sustained response to low dose interferon-alpha in a case of refractory pure red cell aplasia.
P2860
Q24652253-CBCE9FDA-9F5B-4DD8-AAD3-BAF9D5E2DA93Q26866954-FD54E6EA-2ABD-459C-818B-3C10A1790D18Q33343948-D353B203-31B2-4D91-807B-CBF436DFDDC5Q33346561-3992D1C6-67EA-49E1-A7AE-E4CE07E42D83Q33358032-08B312D7-8A58-49D5-A66B-C024171C5383Q33359539-9B096A14-ABD5-4575-ADF0-1480CE8A891AQ33363927-1CB91949-5B93-45C0-8E54-4AD29DEE1A03Q33367861-97A9FA35-11CA-401A-80B4-A42B8C7ACF82Q33369826-C8C43B9E-5F29-4F75-A97F-81F6FEB967ECQ33380135-E923A134-F2FF-4B48-9FC4-3C9985FE916EQ33384219-8D8A569D-C21C-4680-901A-7E341739DA87Q33394149-B03B741E-6C16-4E29-A1E4-2DD87AC437FFQ33394791-A1CAE677-0AC0-48CE-88E8-65C7DFE4B7ABQ33404315-8A655E25-EA1A-4765-9763-55470E667B01Q33410653-024C70D5-AD88-40EC-BF98-EF9083B1A808Q33417439-B9B3590E-8C30-4566-B52B-981D099C78EAQ33428041-E0DFC3DE-3A9D-4314-BDE1-A30081447CA1Q33431172-D6808726-3BD6-4A8B-8FD9-057054D0AC63Q34316187-A405E1C2-ED60-4DC7-9598-128C6D0BF686Q34488656-140B20DD-54CF-4190-8FEA-95E738CEFBEBQ35019920-10930D71-0CA5-41D8-891F-36A820652A14Q35669193-638B7ACE-FFE2-40DE-9F8A-E54CD62E6B0AQ36194538-086B4590-CBD0-4238-9E4A-B293B1F20AF2Q36486302-EF6DBB55-E364-43DD-83FA-922344B78AF8Q36784115-9BA41127-D13B-4264-8349-7A06E3A7CAF0Q36852852-9805B468-D10A-4C50-BB63-6E607AEE06C7Q37754665-96C7B842-FD71-4314-A002-399A86FC9525Q37810065-068022B2-58E1-49B2-9FFD-95BA5E1B5940Q37810067-D2A0E15E-B8E6-457B-ADE9-A08EF7E12920Q37843939-BFCCD618-3A71-441D-A309-9BB07997921FQ37955228-7C4AB665-6591-47CB-8A99-A1E83CB62FDBQ37981576-6CAE4745-9E8E-4587-B41F-4849699F727EQ38065877-DF5571E7-A45F-4927-874F-BB3C80335600Q38108152-5677A330-2E38-4F42-87CD-871FDC2051B0Q38150845-13180B36-0886-44F0-B677-F767947BFF30Q38581833-4EEBD34C-2792-48BF-AD6A-7501B1A796E1Q41693758-2CA97428-0835-4D50-8229-BAFB7D85D74BQ44100215-4EF286A7-D0C5-4A1A-B276-4D370757B1C9Q44402617-EBB71353-E779-49AD-B602-DB51396EBD1EQ45043881-C96478C0-9FD3-4FFE-8040-295F2DFCAE48
P2860
The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
@ast
The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
@en
The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
@nl
type
label
The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
@ast
The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
@en
The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
@nl
prefLabel
The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
@ast
The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
@en
The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
@nl
P2093
P2860
P1476
The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
@en
P2093
E C Gordon-Smith
R Griffiths
S B Killick
W Ouwehand
P2860
P304
P356
10.1046/J.1365-2141.2001.03039.X
P407
P577
2001-09-01T00:00:00Z